SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.62
−3.57%Oct 23, 2026, 20:37 UTC
Summit Therapeutics Inc. and Lunit, Inc. announced a research agreement to evaluate Lunit SCOPE IO for tumor microenvironment analysis supporting Summit’s immuno-oncology development programs with ivonescimab.
Oct 22, 2026, 15:50 UTC
Summit Therapeutics Inc. launched a Phase II/III study of ivonescimab for biliary tract cancer, comparing its survival benefits with established immunotherapy regimens.
Source:Oct 21, 2026, 10:05 UTC
Summit Therapeutics announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group to evaluate ivonescimab with chemotherapy against pembrolizumab or durvalumab in a Phase II/III biliary tract cancer study.
Oct 2, 2026, 06:58 UTC
AstraZeneca and Daiichi Sankyo entered into a clinical collaboration with Summit Therapeutics to test Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers.
Sep 29, 2026, 13:31 UTC
Summit Therapeutics shares surged 23%, marking their largest intraday gain since April 2025.
Source:Sep 29, 2026, 04:01 UTC
Akeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.
Source:Sep 29, 2026, 02:09 UTC
AstraZeneca and Summit Therapeutics announced they will jointly run a series of clinical trials combining ivonescimab with AstraZeneca's cancer therapies, and signed a preliminary agreement to explore ivonescimab combinations with several AstraZeneca antibody-drug conjugates.
Sep 28, 2026, 21:48 UTC
AstraZeneca agreed to invest $2 billion in newly issued preferred equity of Summit Therapeutics, convertible into common stock at a 1:1,000 ratio, representing a common stock price of $18.36 per share.
Sep 23, 2026, 23:59 UTC
Summit Therapeutics and Akeso revealed new study findings for ivonescimab that impressed Wall Street amid dueling data with a rival Merck medication.
Source:Sep 22, 2026, 10:00 UTC
Summit Therapeutics announced that data from the Phase III HARMONi-GI1 trial of ivonescimab plus chemotherapy in first-line advanced biliary tract cancer, sponsored by Akeso, will be presented in the Presidential Symposium at ESMO 2026 in Madrid on October 25, 2026.
Source:Sep 15, 2026, 10:00 UTC
Summit Therapeutics presented updated overall survival results from the global Phase III HARMONi clinical trial of ivonescimab plus chemotherapy in Western and Asian patients at WCLC 2026 in Seoul, Republic of Korea.
Source:Jul 24, 2026, 15:53 UTC
Summit Therapeutics raised $230.8 million in gross proceeds through its ATM facility in Q2 2026 and an additional $68.4 million after the quarter.
Source:Jul 24, 2026, 02:40 UTC
Summit Therapeutics Inc. held its Q2 2026 earnings call.
Source:Jul 22, 2026, 20:30 UTC
Arcus Biosciences and Summit Therapeutics entered into a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer.
Source:Jul 14, 2026, 11:00 UTC
Summit Therapeutics signed an agreement to sell its Phase III asset ridinilazole to Biossil, Inc.
Source:Jun 11, 2026, 00:00 UTC
Summit Therapeutics canceled its planned $500 million secondary share offering one day after announcing it, citing market conditions.
Source:May 31, 2026, 12:00 UTC
Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.